智通财经APP讯，心通医疗-B(02160)发布截至2024年12月31日止年度的全年业绩，收入3.62亿元(人民币，下同)，同比增加7.54%;股东应占亏损4944.6万元，同比收窄89.51%;每股基本亏损0.02元。
公告称，收入增长主要是由于报告期内，VitaFlow Liberty®及Alwide® Plus在全球商业化的持续推进，促进了TAVI产品的海外收入高速增长。此外，于报告期内，集团的附属公司上海佐心自主研发的AnchorMan®左心耳封堵系统及AnchorMan®左心耳导引系统在中国正式商业化，亦为集团带来新增收入贡献。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.